Abstract
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P < .05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 107-108 |
| Number of pages | 2 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 50 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2004 |